PARIS (Reuters) - The French government needs guarantees from drugmaker Sanofi that production of its popular Doliprane ...

Sanofi, which is joining a growing number of drugmakers shedding consumer related businesses, said Opella had been valued at ...

Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, ...

Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% ...

PARIS (Reuters) -French unions have called on workers at Sanofi to strike from Thursday to protest a planned sale of the ...

French pharamceutical giant Sanofi has confirmed plans to sell a controlling stake in its over-the-counter unit to a US ...

Sanofi will sell a 50% controlling stake in consumer healthcare unit Opella to private equity firm CD&R, with the French ...

French drugmaker Sanofi's Monday confirmation that it plans to sell a controlling stake in its over-the-counter unit to a US ...

Under the proposed deal, the PE firm would take a controlling 50% stake in Sanofi’s Opella unit, with state-owned Bpifrance taking a minority 2% position.

Sanofi is in talks with CD&R to sell a 50% stake in its consumer healthcare unit, Opella. PAI Partners raised its bid by 200 ...

Sanofi said. Bpifrance is expected to participate as a minority shareholder with a c.2% stake. Headquartered in France, Opella employs over 11,000 people, operates in 100 countries with 13 ...

France will take a stake in Sanofi’s Opella through the Public Investment Bank, or BPI, finance minister Antoine Armand said on Sunday, confirming an information from Le Figaro ...